FDA panel admonishes Merck with a gentle — and rare — slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC

Merck is going to have to wait longer before the FDA considers opening the door to using Keytruda as an adjuvant therapy for high risk …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA pan­el ad­mon­ish­es Mer­ck with a gen­tle — and rare — slap­down for rush­ing its pitch on an ac­cel­er­at­ed OK for ad­ju­vant Keytru­da in TNBC